{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"15"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Progressive Disease (PD)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Defined as the best response recorded from the start of treatment until disease progression/recurrence, evaluated according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1 for target lesions and assessed by MRI: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = at least a 30% decrease in the sum of the diameters of the target lesions compared to the baseline; Stable Disease = Neither enough shrinkage for PR nor enough growth for PD; Progressive Disease = at least a 20% increase in the sum of the diameters of the target lesions from the smallest measurement recorded, with an absolute increase of at least 5 mm, or the appearance of one or more new lesions.","groups":[{"description":"paclitaxel, gemcitabine, and oxaliplatin:\n\n1. Paclitaxel 170 mg/m2 IV d 1 14 days\n2. Gemcitabine 800 mg/m2 IV d 1 14 days\n3. Oxaliplatin 100 mg/m2 IV d 1 14 days","id":"OG000","title":"Paclitaxel, Gemcitabine, and Oxaliplatin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 patient was inevaluable.","reportingStatus":"POSTED","timeFrame":"From start of study drug until the date of first documented progression or date of death from any cause, whichever came first, assessed every 6 weeks, through study completion, up to 9 years","title":"Tumor Response","type":"PRIMARY","unitOfMeasure":"Participants"}